Skip to content

LBRX LBRX Accrued Liabilities, Current

Accrued Liabilities, Current at other companies

MapLight Therapeutics, Inc.
 logo
MapLight Therapeutics, Inc. MPLT
Alto Neuroscience logo
Alto NeuroscienceANRO
Opko Health logo
Opko HealthOPK
Acadia Pharmaceuticals logo
Acadia PharmaceuticalsACAD
Septerna, Inc. logo
Septerna, Inc.SEPN
Rapport Therapeutics, Inc. logo
Rapport Therapeutics, Inc.RAPP

Other financials

Income statement

See full
Net income-$19.1M-259%
EPS (diluted)-$0.67+95.5%

Balance sheet

See full
Cash & equivalents$320.7M
Total debt$3.5M
Total equity$378.7M+481%
Total assets$393.5M

Cash flow

See full
Operating cash flow-$23.3M-187%
CapEx$32.0K+52.4%
Free cash flow-$23.3M-186%

Valuation

See full
Market cap$888.98M+163%
Enterprise value$571.77M

Returns & leverage

See full
Return on equity-27.9%
Debt / equity
Current ratio35.7×

Where this comes from

Reported directly by LBRX in its filing.

Tagged under the XBRL concept us-gaap:AccruedLiabilitiesCurrent.

The official record: LBRX’s 10-Q, filed May 12, 2026, on SEC EDGAR. View the filing →

Ask your AI about LBRX's accrued liabilities, current.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is LBRX's accrued liabilities, current?
LBRX (LBRX) reported accrued liabilities, current of $3.06M in Q1 2026.